Figure 5 | Nutrition & Diabetes

Figure 5

From: The cannabinoid Δ9-tetrahydrocannabivarin (THCV) ameliorates insulin sensitivity in two mouse models of obesity

Figure 5Figure 5

Effect of THCV on insulin-induced phosphorylation of Akt in insulin-resistant human HHL-5 hepatocytes. (b, c) HHL-5 cells were rendered insulin-resistant following 72 h incubation with 100 nM insulin (Ins.) (b) or 48 h incubation with 0.25 mM palmitic acid (PA) (c). A representative western blot for insulin stimulation of Akt phosphorylation in insulin-sensitive cells is shown in (a), the right panel indicating the fold-stimulation by insulin of basal phosphoAkt (pAKT)/total Akt (AKT), quantified by densitometry in absence (DMSO) or presence of THCV 1–10 μM. (b, c) Representative western blots for insulin stimulation of Akt phosphorylation in insulin-resistant hepatocytes incubated for the final 24 h of chronic insulin or PA incubation with the indicated concentrations of THCV. The middle panels, obtained by densitometry quantification of n=3 separate western blots, indicate the lower stimulation by acute insulin of pAKT/AKT levels in desensitized cells as compared to insulin-sensitive cells (naïve), considered as 1. The right panels indicate the effect of THCV on insulin-induced stimulation of pAKT/AKT levels in insulin-resistant cells as compared with insulin-resistant cells only treated with acute insulin and THCV vehicle (DMSO), considered as 1. (d, e) Representative western blots for insulin stimulation of Akt phosphorylation in hepatocytes made insulin-resistant with a 24-h treatment with insulin or PA and co-incubated with the indicated concentrations of THCV, AM251 or vehicle. The middle panels, obtained by densitometry quantification of n=3 separate western blots, indicate the lower stimulation by acute insulin of pAKT/AKT levels in desensitized cells as compared with insulin-sensitive cells (naïve), considered as 1. The right panels indicate the effect of THCV or AM251 on insulin-induced stimulation of pAKT/AKT levels in insulin-resistant cells as compared with insulin-resistant cells only treated with acute insulin and vehicle (DMSO), considered as 1. #P<0.05 or ##P<0.01 vs naïve. *P<0.05 or **P<0.01 vs DMSO, as assessed by ANOVA followed by the Bonferroni’s test.

Back to article page